Advanced search
Publication Cover
Cancer Biology & Therapy Volume 15, 2014 - Issue 6
Submit an article Journal homepage
1,631
Views
13
CrossRef citations to date
0
Altmetric
Research Paper

A novel lead compound CM-118

Antitumor activity and new insight into the molecular mechanism and combination therapy strategy in c-Met- and ALK-dependent cancers

Lanfang Meng Department of Pharmacology; Fudan University School of Pharmacy; Shanghai, PR China; Department of Nuclear Medicine; Zhongshan Hospital; Fudan University; Shanghai, PR China
,
Mengjun Shu School of Pharmacy; Shanghai Jiaotong University; Shanghai, PR China
,
Yaqing Chen Department of Pharmacology; Fudan University School of Pharmacy; Shanghai, PR China
,
Dexiao Yang Sundia MediTech; Shanghai, PR China
,
Qun He Department of Pharmacology; Fudan University School of Pharmacy; Shanghai, PR China
,
Hui Zhao Department of Pharmacology; Fudan University School of Pharmacy; Shanghai, PR China
,
Zhiyong Feng Sundia MediTech; Shanghai, PR China
,
Chris Liang Xcovery Inc.; West Palm Beach, FL USA
&
Ker Yu Department of Pharmacology; Fudan University School of Pharmacy; Shanghai, PR ChinaCorrespondence[email protected]
 show all
Pages 721-734 | Received 30 Nov 2013, Accepted 03 Mar 2014, Published online: 11 Mar 2014

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Somayeh Pirhadi, Tahereh Damghani, Mohammad Sadegh Avestan & Shahrzad Sharifi. (2020) Dual potent c-Met and ALK inhibitors: from common feature pharmacophore modeling to structure based virtual screening. Journal of Receptors and Signal Transduction 40:4, pages 357-364.
Read now
Paul Dent. (2014) Met in lung cancer. Cancer Biology & Therapy 15:6, pages 653-654.
Read now

Articles from other publishers (11)

Hua Gao, Jing-Yi Zhang, Li-Jie Zhao & Yuan-Yuan Guo. (2023) Synthesis and clinical application of small-molecule inhibitors and PROTACs of anaplastic lymphoma kinase. Bioorganic Chemistry 140, pages 106807.
Crossref
Monika Caban, Bettina Koblmueller, Diana Groza, Hemma H. Schueffl, Alessio Terenzi, Alexander Tolios, Thomas Mohr, Marlene Mathuber, Kushtrim Kryeziu, Carola Jaunecker, Christine Pirker, Bernhard K. Keppler, Walter Berger, Christian R. Kowol & Petra Heffeter. (2023) A novel EGFR inhibitor acts as potent tool for hypoxia-activated prodrug systems and exerts strong synergistic activity with VEGFR inhibition in vitro and in vivo. Cancer Letters 565, pages 216237.
Crossref
Tabbisa Namulinda, Lei-Lei Bao, Justus Kwetegyeka, Ivan Gumula, Yi-Jia Yan & Zhi-Long Chen. (2023) Antibacterial and anticancer activities of green-synthesized silver nanoparticles using Photinia glabra fruit extract . Nanomedicine 18:14, pages 987-1002.
Crossref
Julie Bolcaen, Shankari Nair, Cathryn Driver, Tebatso Boshomane, Thomas Ebenhan & Charlot Vandevoorde. (2021) Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma. Pharmaceuticals 14:7, pages 626.
Crossref
Mengjun Shu, Fengjiao He, Zhaohui Li, Xingzhong Zhu, Yujie Ma, Zhihua Zhou, Zhi Yang, Feng Gao & Min Zeng. (2020) Biosynthesis and Antibacterial Activity of Silver Nanoparticles Using Yeast Extract as Reducing and Capping Agents. Nanoscale Research Letters 15:1.
Crossref
Mengjun Shu, Feng Gao, Chulang Yu, Min Zeng, Guili He, Yan Wu, Yanjie Su, Nantao Hu, Zhihua Zhou, Zhi Yang & Lin Xu. (2020) Dual-targeted therapy in HER2-positive breast cancer cells with the combination of carbon dots/HER3 siRNA and trastuzumab. Nanotechnology 31:33, pages 335102.
Crossref
Qingyu Lin, Yingying Zhang, Zhequan Fu, Bingxin Hu, Zhan Si, Yanzhao Zhao, Hongcheng Shi & Dengfeng Cheng. (2020) Synthesis and evaluation of 18F labeled crizotinib derivative [18F]FPC as a novel PET probe for imaging c-MET-positive NSCLC tumor. Bioorganic & Medicinal Chemistry 28:15, pages 115577.
Crossref
Fangling Cheng & Dongsheng Guo. (2019) MET in glioma: signaling pathways and targeted therapies. Journal of Experimental & Clinical Cancer Research 38:1.
Crossref
Qianwen Zhang, Yan Zhang, Yaqing Chen, Jianchang Qian, Xuesai Zhang & Ker Yu. (2019) A Novel mTORC1/2 Inhibitor (MTI-31) Inhibits Tumor Growth, Epithelial–Mesenchymal Transition, Metastases, and Improves Antitumor Immunity in Preclinical Models of Lung Cancer. Clinical Cancer Research 25:12, pages 3630-3642.
Crossref
Ronit Vogt Sionov, Spiros A. Vlahopoulos & Zvi Granot. (2015) Regulation of Bim in Health and Disease. Oncotarget 6:27, pages 23058-23134.
Crossref
Jae Eun Kim, Qun He, Yaqing Chen, Celine Shi & Ker Yu. (2014) mTOR-targeted therapy: Differential perturbation to mitochondrial membrane potential and permeability transition pore plays a role in therapeutic response. Biochemical and Biophysical Research Communications 447:1, pages 184-191.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.